View Company News: See Articles

Cappella is focused on developing novel coronary stent technologies designed to treat bifurcated lesions.

The Sideguard™ Bifurcation Stenting System will be the first drug-eluting side branch, Ostium Protection Device (OPD) ™ in interventional cardiologists’ arsenal against restenosis for ostial-bifurcation lesions. The Sideguard™ Bifurcation Stenting System has a unique balloon-assisted delivery system for precise deployment.

Cappella has commenced its First-In-Man (FIM) clinical trials enrolling 30 patients at three sites in Europe.